Coya Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Coya is a clinical-stage biotechnology company developing therapies intended to enhance regulatory T-cell function. It has no product sales and remains dependent on financing and collaboration income.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Collaboration revenue | $126,838 | $0 |
| Research and development expense | $3.14 million | $1.23 million |
| General and administrative expense | $2.44 million | $1.66 million |
| Total operating expenses | $5.61 million | $2.90 million |
| Operating loss | $5.48 million | $2.90 million |
| Net loss | $5.05 million | $2.74 million |
| Net loss per share, basic and diluted | $0.35 | $0.28 |
| Cash and cash equivalents, at period end | $35.99 million | $16.32 million |
- Cash provided by operating activities was $2.15 million, versus $3.86 million used in Q1 2023. The 2024 inflow reflected receipt of the $7.5 million DRL upfront payment; it should not be read as evidence of positive underlying operating performance.
- Financing activities provided $1.24 million, primarily from warrant exercises; investing activities used $25,000.
- Total liabilities were $5.00 million, all reported as current or deferred collaboration revenue; the filing reports no debt. Stockholders’ equity was $32.39 million.
- The filing does not present a gross margin, and product revenue has not begun.
Changes versus the prior comparable period
- Net loss increased by $2.32 million year over year as operating expenses rose by $2.71 million, partly offset by $0.13 million in collaboration revenue and higher other income.
- R&D expense increased by $1.91 million, mainly from COYA 300 Series preclinical work preparing COYA 302 for an IND filing and Phase 2 trial; G&A expense increased by $0.78 million, primarily from personnel and consulting costs.
- Cash increased by $3.36 million during the quarter, compared with a $10.39 million increase in Q1 2023, when the IPO generated substantial financing proceeds.
Outlook, developments and risks
- Management estimates that the $35.99 million cash balance will fund operating expenses and capital expenditures into 2026. The company expects to need additional funding then, and states that estimates may prove imprecise and cash could be used sooner.
- Management expects expenses and R&D spending to rise in 2024, with focus on COYA 301 and COYA 302. It planned to submit a COYA 302 ALS IND in Q2 2024, initiate a Phase 2 trial following FDA acceptance, and submit a COYA 302 FTD IND before year-end 2024. These are stated plans, not reported outcomes.
- Coya reported plans to expand COYA 302 development to FTD, Parkinson’s disease and Alzheimer’s disease. It anticipated summer 2024 topline data from an academic Phase 2 low-dose IL-2 Alzheimer’s study; the filing does not report those results.
- The DRL Development Agreement provides a $7.5 million nonrefundable upfront payment, received in January 2024, and potential additional payments of $4.2 million on FDA acceptance of the COYA 302 ALS IND and $4.2 million on first patient dosing in the first U.S. Phase 2 trial. Further development and sales milestones are contingent and are not assured.
- Under the agreement, DRL has an exclusive license to commercialize COYA 302 for ALS in the United States, Canada, EU and UK. Coya is responsible for specified clinical development and U.S. regulatory work; royalties are described as low-to-mid teens before royalties owed under other licenses. A commercial supply agreement had not been entered into as of the filing.
- The company has incurred losses since inception, had a $30.9 million accumulated deficit, and expects further losses. It says substantial additional financing will be needed; no assurance is given that financing will be available. Failure to raise capital could delay, scale back or stop development.
- Other key risks include clinical and regulatory uncertainty, reliance on third-party licenses and collaborators, ability to protect intellectual property, and dependence on external funding. The filing says there were no material changes to previously disclosed risk factors, no outstanding legal proceedings, and no material changes in internal control over financial reporting.
Important facts for investors to verify
- Whether the COYA 302 ALS IND was filed in Q2 2024 and accepted by the FDA, and whether the related $4.2 million milestone became payable.
- Whether the first patient was dosed in the planned U.S. Phase 2 trial, triggering the additional $4.2 million payment, and whether trial timing or costs changed.
- Whether the cash runway remains consistent with management’s estimate of funding into 2026, particularly as R&D spending increases.
- Whether the expected Alzheimer’s study data and planned FTD development milestones were achieved, and how results affect Coya’s clinical plans.
- Whether Coya and DRL agreed on commercial supply terms, and whether contingent milestones or royalties ultimately generate material cash receipts.
- Potential dilution or cash proceeds from equity and warrant activity; the filing reported 14,613,172 common shares outstanding at March 31, 2024 and 14,618,172 at May 7, 2024.